CheckMan Stock Market Overview
Trending Stocks
Red List
In Today's Headlines
Palantir is back on every screen this month, up 14.55% in a single week as retail traders pile back into the AI infrastructure trade that briefly wobbled in June.
Every feed you open right now has the same story: Dell Technologies (NYSE:DELL | DELL Price Prediction) is on a tear.
President Trump announced a new blockade and tolls on the Strait of Hormuz while investors remained jittery about tech stocks.
CEG adds nearly 10 GW of power capacity as AI, data centers, electrification and U.S. manufacturing drive electricity demand.
Extra Space Storage benefits from resilient demand, acquisitions and steady expansion, though new supply and higher debt remain headwinds.
CENT is improving efficiency through cost discipline, simplification and operational changes that support long-term profitability.
BENSALEM, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
NEW YORK, July 13, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Intuit Inc. (NASDAQ: INTU) between August 22, 2025 and May 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed.
BENSALEM, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS) colon cancer. The financing includes approximately $85 million in upfront gross proceeds, with an additional potential $255 million available through the full exercise of purchase warrants.